Posts

Biogen flips 2026 revenue guidance from expected decline to sales increase

on

Biogen's Tau-Targeting Alzheimer's Drug Shows Promising but Confusing Results

on

AAIC 2026：Biogen公布抗tau反义寡核苷酸药物详细数据，抗tau领域初现曙光

on

Questions linger over Biogen's tau drug for Alzheimer's, as low dose reports better results

on

Eisai, Biogen scoop up subQ Leqembi starter‑dose nod – FDA greenlights subcutaneous lecanemab initiation for early Alzheimer’s disease

on

Biogen trims Apellis R&D after $5.6B acquisition, focuses on Empaveli and Syfovre

on

Biogen acquires RayThera in up to $1B deal to bolster preclinical immunology pipeline

on

City Therapeutics raises $99.5M to advance three RNAi programs and its next‑generation platform

on

Italy probes Biogen for allegedly hindering sales of rival's MS drug

on

Biogen and Denali halt Parkinson’s drug in non‑genetic Parkinson’s after mid‑stage failure

on

Biogen advances anti-tau Alzheimer’s drug diranersen despite mixed Phase 2 results

on

Biogen advances Alzheimer’s tau program despite midphase miss

on

FDA Extends Review of LEQEMBI IQLIK Subcutaneous Starting Dose for Early Alzheimer's Disease

on

FDA Action Alert: Upcoming Decisions on Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai, and Cingulate

on

Biogen Pursues Early-Stage Assets to Build Next Generation Growth Pipeline

on

Biogen's Post-Apellis Strategy: Expanding Early-Stage Pipeline to Drive Next-Generation Growth

on

Biogen Acquires Exclusive Rights to Felzartamab in Greater China Region from TJ Biopharma

on

Biogen's $5.6B Apellis Acquisition: Key Biotech Deals Including Telix's $600M Raise and Obsidian's IPO Plans

on

Post-Hoc Live: Biopharma M&A Surge Signals Industry Revival

on

Pharma’s M&A Train Is on Track for Record Highs With More Deals To Come: Analysts

on